Monitoring Agency Report for the quarter ended 30th June, 2026

SUVEN® Life Sciences CSD/BM/SE/2026-27 Date: August 11, 2026 To To Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 530239 Scrip Symbol: SUVEN Dear Sir/Madam, Sub: Monitoring Agency Report for the quarter ended June 30, 2026 Pursuant to Regulation 162A of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018 and Regulation 32 (6) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Monitoring Agency (MA) Report issued by CRISIL Ratings Limited for the quarter ended June 30, 2026, regarding utilization of proceeds of the Preferential Issue of the Company. This is for your information and records. Thanking you. Yours faithfully, For Suven Life Sciences Limited K. Sangeetha Laxmi Company Secretary and Compliance officer Encl: as above Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com Crisil Ratings Monitoring Agency Report for Suven Life Sciences Limited for the quarter ended June 30, 2026 Crisil Ratings Limited Corporate Identity Number: U671 OOMH2019PLC326247 Registered Office: Lightbridge IT Park, Saki Vihar Road, Andheri East, Mumbai-400 072. India Phone: +91 22 6137 3000 I www.crisilratings.com a company of S&P Global Crisil Ratings CRL/MAR/ SUVPHAR/2026-27/1909 August 10, 2026 Suven Life Sciences Limited 8-2-334, SDE Serene Chambers Road, Road No. 5, Avenue 7, Banjara Hills, Hyderabad–500034 Dear Sir, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the Preferential Issue of Suven Life Sciences Limited (“the Company”) Pursuant to Regulation 162A of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and Monitoring Agency Agreement dated May 15, 2025, enclosed herewith the Monitoring Agency Report, issued by Crisil Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of Preferential Issue for the quarter ended June 30, 2026. Request you to kindly take the same on records. Thanking you, For and on behalf of Crisil Ratings Limited Shounak Chakravarty Director, Ratings (LCG) Crisil Ratings Limited Corporate Identity Number: U671 OOMH2019PLC326247 Registered Office: Lightbridge IT Park, Saki Vihar Road, Andheri East, Mumbai-400 072. India Phone: +91 22 6137 3000 I www.crisilratings.com a company of S&P Global Crisil Ratings Report of the Monitoring Agency (MA) Name of the issuer: Suven Life Sciences Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: Crisil Ratings Limited (a) Deviation from the objects: Not applicable (b) Range of Deviation: Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Shounak Chakravarty Designation of Authorized person/Signing Authority: Director, Ratings (LCG) Crisil Ratings Limited Corporate Identity Number: U671 OOMH2019PLC326247 Registered Office: Lightbridge IT Park, Saki Vihar Road, Andheri East, Mumbai-400 072. India Phone: +91 22 6137 3000 I www.crisilratings.com a company of S&P Global Crisil Ratings 1) Issuer Details: Name of the issuer: Suven Life Sciences Limited Names of the promoter: a. Venkateswarlu Jasti b. Sudharani Jasti Industry/sector to which it belongs: Pharmaceuticals 2) Issue Details Issue Period: June 21, 2025 to June 30, 2025 Type of issue (public/rights): Preferential Issue Type of specified securities: Convertible Warrants Grading, if any: NA Issue size: Rs 85,764.02 lakhs* Preferential Issue size comprises of convertible warrants of Rs 85,764.02 lakhs. *Crisil Ratings shall be monitoring the issue proceeds amount. 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information/ certifications Comments of Comments considered by the of the Particulars Reply Monitoring Agency Monitoring Board of for preparation of Agency Directors report Proceeds were Management utilized undertaking, Statutory towards Auditor Certificate^, objects Whether all utilization is as per the disclosures Notice to shareholders No Yes disclosed in in the Offer Document? dated May 14th, 2025, Comments the notice to Corrigendum to notice shareholders dated 28th May 2025, dated May Bank Statements 14th, 2025. Crisil Ratings Limited Corporate Identity Number: U671 OOMH2019PLC326247 Registered Office: Lightbridge IT Park, Saki Vihar Road, Andheri East, Mumbai-400 072. India Phone: +91 22 6137 3000 I www.crisilratings.com a company of S&P Global Crisil Ratings Whether shareholder approval has been obtained in case of material deviations from No NA No Comments expenditures disclosed in the Offer Comments Document? Whether the means of finance for the disclosed No NA No Comments objects of the issue has changed? Comments Is there any major deviation observed over the No NA No Comments earlier monitoring agency reports? Comments Whether all Government/statutory approvals No NA No Comments related to the object(s) have been obtained? Management Comments undertaking, Statutory Auditor Certificate^ Whether all arrangements pertaining to technical assistance/collaboration are in NA No Comments Comments operation? Are there any favorable events improving the No No No Comments viability of these object(s)? Comments Are there any unfavorable events affecting the No No No Comments viability of the object(s)? Comments Is there any other relevant information that may materially affect the decision making of No No Comments Comments the investors? NA represents Not Applicable ^Certificate dated July 21, 2026, issued by M/s K [Showing first 8,000 characters — download PDF for full document]